Advisory Research’s Supernus Pharmaceuticals SUPN Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $580K | Buy |
18,397
+1,175
| +7% | +$37K | 0.09% | 122 |
|
|
2025
Q1 | $564K | Buy |
17,222
+43
| +0.3% | +$1.41K | 0.1% | 122 |
|
|
2024
Q4 | $621K | Buy |
17,179
+82
| +0.5% | +$2.97K | 0.1% | 126 |
|
|
2024
Q3 | $533K | Buy |
17,097
+331
| +2% | +$10.3K | 0.09% | 132 |
|
|
2024
Q2 | $448K | Buy |
16,766
+1,069
| +7% | +$28.6K | 0.08% | 139 |
|
|
2024
Q1 | $535K | Sell |
15,697
-811
| -5% | -$27.7K | 0.11% | 128 |
|
|
2023
Q4 | $478K | Sell |
16,508
-1,030
| -6% | -$29.8K | 0.07% | 241 |
|
|
2023
Q3 | $484K | Sell |
17,538
-554
| -3% | -$15.3K | 0.07% | 284 |
|
|
2023
Q2 | $544K | Buy |
18,092
+713
| +4% | +$21.4K | 0.07% | 279 |
|
|
2023
Q1 | $630K | Buy |
17,379
+217
| +1% | +$7.86K | 0.1% | 223 |
|
|
2022
Q4 | $612K | Sell |
17,162
-9,562
| -36% | -$341K | 0.06% | 227 |
|
|
2022
Q3 | $905K | Buy |
26,724
+93
| +0.3% | +$3.15K | 0.09% | 176 |
|
|
2022
Q2 | $770K | Buy |
26,631
+2,400
| +10% | +$69.4K | 0.08% | 184 |
|
|
2022
Q1 | $783K | Buy |
+24,231
| New | +$783K | 0.06% | 210 |
|